New combo therapy aims to reignite immune attack on brain tumors
Disease control
Recruiting now
This study tests a combination of two drugs—ATRA and retifanlimab—in people with a recurrent type of brain tumor called IDH-mutant glioma. The goal is to see if this treatment can shrink tumors or slow their growth by boosting the body's immune response. About 55 participants wil…
Phase: PHASE2 • Sponsor: Stephen Bagley, MD, MSCE • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC